* BIOLASE Inc BIOL.OQ BIOL.O is expected to show a fall
in
quarterly revenue when it reports results on May 13 for the
period ending March 31 2024
* The Foothill Ranch California-based company is expected
to
report a 4.5% decrease in revenue to $9.996 million from $10.47
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.The company's guidance on March 21
2024, for the period ended March 31, was for revenue of $10.467
million.
* LSEG's mean analyst estimate for BIOLASE Inc is for a
loss
of 17 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 9.2%
in the last three months.
* Wall Street's median 12-month price target for BIOLASE Inc
is
$2.25, above its last closing price of $0.18.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -3.31 -2.55 -1.76 Beat 31.1
Sep. 30 2023 -1.85 -1.85 -3.89 Missed -110.3
Jun. 30 2023 -4.00 -5.33 -8.24 Missed -54.5
Jan. 1 0001 -21.31 -19.67 -18.00 Beat 8.5
Dec. -64.18 -63.67 -1.28 Missed -101
31 2022 hundred
Sep. 30 2022 -84.76 -84.33 -1.10 Missed -30.4
hundred
Jun. 30 2022 -63.50 -62.25 -91.00 Missed -46.2
Mar. 31 2022 -79.00 -68.00 -81.00 Missed -19.1
This summary was machine generated May 7 at 11:29 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)